Mac-2 binding protein and galectin-3 expression in mucinous tumours of the ovary: An annealing control primer system and immunohistochemical study

Pathology

Volumn 41, Issue 3, 2009, Pages 229-233

  Lee, Ju Han ^a   Zhang, Xianglan ^a   Kyung Shin, Bong ^a   Seok Lee, Eung ^a   Kim, Insun ^a  

^a Korea University   (South Korea)

Author keywords

Galectin 3; Mac 2 binding protein; Mucinous tumour; Ovary

Indexed keywords

BINDING PROTEIN; COMPLEMENTARY DNA; DNA; GALECTIN 3; MAC 2 BINDING PROTEIN; MUCIN; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; MEMBRANE PROTEIN; PRIMER DNA; TAA90K PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR MARKER;

ANNEALING CONTROL PRIMER SYSTEM; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENE IDENTIFICATION; GENE TARGETING; GENETIC ANALYSIS; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MUCINOUS CARCINOMA; NUCLEOTIDE SEQUENCE; OVARY ADENOCARCINOMA; OVARY CARCINOMA; OVARY TUMOR; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; BIOSYNTHESIS; CYSTADENOCARCINOMA; FEMALE; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; METHODOLOGY; TISSUE MICROARRAY;

ANTIGENS, NEOPLASM; CYSTADENOCARCINOMA, MUCINOUS; DNA PRIMERS; FEMALE; GALECTIN 3; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; MEMBRANE GLYCOPROTEINS; OVARIAN NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 68849101942     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1080/00313020902756279     Document Type: Article

References (25)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43-66.
2. Harrison ML, Jameson C, Gore ME. Mucinous ovarian cancer. Int J Gynecol Cancer 2008; 18: 209-214
3. Fujita M, Enomoto T, Murata Y. Genetic alterations in ovarian carcinoma: with specific reference to histological subtypes. Mol Cell Endocrinol 2003; 202: 97-99
4. Pieretti M, Hopenhayn-Rich C, Khattar NH, Cao Y, Huang B, Tucker TC. Heterogeneity of ovarian cancer: relationships among histological group, stage of disease, tumor markers, patient characteristics, and survival. Cancer Invest 2002; 20: 11-23.
5. Hwang IT, Kim YJ, Kim SH, Kwak CI, Gu YY, Chun JY. Annealing control primer system for improving specificity of PCR amplification. Biotechniques 2003; 35: 1180-1184
6. Iacobelli S, Arno E, D'Orazio A, Coletti G. Detection of antigens recognized by a novel monoclonal antibody in tissue and serum from patients with breast cancer. Cancer Res 1986; 46: 3005-3010
7. Koths K, Taylor E, Halenbeck R, Casipit C, Wang A. Cloning and characterization of a human Mac-2-binding protein, a new member of the superfamily defined by the macrophage scavenger receptor cysteine-rich domain. J Biol Chem 1993; 268: 14245-14249
8. Ullrich A, Sures I, D'Egidio M, et al. The secreted tumor-associated antigen 90K is a potent immune stimulator. J Biol Chem 1994; 269: 18401-18407
9. Inohara M, Akahani S, Koths K, Raz A. Interactions between galectin-3 and Mac-2 binding protein mediate cell-cell adhesion. Cancer Res 1996; 56: 4530-4534
10. Inohara H, Akahani S, Raz A. Galectin-3 stimulates cell proliferation. Exp Cell Res 1998; 245: 294-302.
11. Matarrese P, Fusco O, Tinari N, et al. Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties. Int J Cancer 2000; 85: 545-554 (Pubitemid 30075135)
12. Nangia-Makker P, Honjo Y, Sarvis R, et al. Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am J Pathol 2000; 156: 899-909.
13. Barondes SH, Cooper DN, Gitt MA, Leffler H. Galectins. Structure and function of a large family of animal lectins. J Biol Chem 1994; 269: 20807-20810
14. Grassadonia A, Tinari N, Iurisci I, et al. 90K (Mac-2 BP) and galectins in tumor progression and metastasis. Glycoconj J 2004; 19: 551-556
15. Linsley PS, Horn D, Marquardt H, et al. Identification of a novel serum protein secreted by lung carcinoma cells. Biochemistry 1986; 25: 2978-2986
16. Rea A, Calmieri G, Tinari N, et al. 90K is a serum marker of poor prognosis in non-Hodgkin's lymphoma patients. Oncol Rep 1994; 1: 723-725
17. Scambia G, Panici PB, Baiocchi G, Perrone L, Iacobelli S, Mancuso S. Measurement of a monoclonal-antibody-defined antigen (90K) in the sera of patients with ovarian cancer. Anticancer Res 1988; 8: 761-764 (Pubitemid 18232000)
18. Zeimet AG, Natoli C, Herold M, et al. Circulating immunostimulatory protein 90K and soluble interleukin-2-receptor in human ovarian cancer. Int J Cancer 1996; 68: 34-38
19. Koopmann J, Thuluvath PJ, Zahurak ML, et al. Mac-2 binding protein is a diagnostic marker for biliary tract carcinoma. Cancer 2004; 101: 1609-1615
20. Kunzli BM, Berberat PO, Zhu ZW, et al. Influences of the lysosomal associated membrane proteins (Lamps-1, Lamps-2) and Mac-2 binding protein (Mac-2 BP) on the prognosis of pancreatic carcinoma. Cancer 2002; 94: 228-239
21. Marchetti A, Tinari N, Buttitta F, et al. Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I nonsmall cell lung cancer patients. Cancer Res 2002; 62: 2535-2539
22. Park YP, Choi SC, Kim JH, et al. Up-regulation of Mac-2 binding protein by hTERT in gastric cancer. Int J Cancer 2006; 120: 813-820
23. Ulmer TA, Keeler V, Loh L, et al. Tumor-associated antigen 90K/ Mac-2-binding protein: Possible role in colon cancer. J Cell Biochem 2006; 98: 1351-1366
24. van den Brule FA, Berchuck A, Bast RC, et al. Differential expression of the 67-kD laminin receptor and 31-kD human lamininbinding protein in human ovarian carcinomas. Eur J Cancer 1994; 30: 1096-1099
25. Iurisci I, Tinari N, Natoli C, Angelucci D, Cianchetti E, Iacobelli S. Concentrations of galectin-3 in the sera of normal controls and cancer patients. Clin Cancer Res 2000; 6: 1389-1393